Literature DB >> 15229631

Highly specific transgene expression mediated by a complex adenovirus vector incorporating a prostate-specific amplification feedback loop.

J Woraratanadharm1, S Rubinchik, H Yu, F Fan, S M Morrow, J Y Dong.   

Abstract

Development of novel therapeutic agents is needed to address the problems of locally recurrent, metastatic, and advanced hormone-refractory prostate cancer. We have constructed a novel complex adenovirus (Ad) vector regulation system that incorporates both the prostate-specific ARR2PB promoter and a positive feedback loop using the TRE promoter to enhance gene expression. This regulation strategy involves the incorporation of the TRE upstream of the prostate-specific ARR2PB promoter to enhance its activity with Tet regulation. The expressions of both GFP and tTA were placed under the control of these TRE-ARR2PB promoters, so that in the cells of prostate origin a positive feedback loop would be generated. This design greatly enhanced GFP reporter expression in prostate cancer cells, while retaining tight control of expression in nonprostate cancer cells, even at an MOI as high as 1000. This novel positive feedback loop with prostate specificity (PFLPS) regulation system we have developed may have broad applications for expressing not only high levels of toxic proteins in cancer cells, but alternatively could also be manipulated to regulate essential genes in a highly efficient conditionally replicative adenovirus vector specifically directed to prostate cancer cells. The PFLPS regulation system, therefore, serves as a promising new approach in the development of both a specific and effective vector for cancer gene therapy.

Entities:  

Mesh:

Year:  2004        PMID: 15229631      PMCID: PMC1831545          DOI: 10.1038/sj.gt.3302307

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  50 in total

1.  Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors.

Authors:  J G Wesseling; P J Bosma; V Krasnykh; E A Kashentseva; J L Blackwell; P N Reynolds; H Li; M Parameshwar; S M Vickers; E M Jaffee; K Huibregtse; D T Curiel; I Dmitriev
Journal:  Gene Ther       Date:  2001-07       Impact factor: 5.250

2.  Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain.

Authors:  Elena A Kashentseva; Toshiro Seki; David T Curiel; Igor P Dmitriev
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

3.  Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors.

Authors:  D A Heideman; P J Snijders; M E Craanen; E Bloemena; C J Meijer; S G Meuwissen; V W van Beusechem; H M Pinedo; D T Curiel; H J Haisma; W R Gerritsen
Journal:  Cancer Gene Ther       Date:  2001-05       Impact factor: 5.987

4.  Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters.

Authors:  S Rubinchik; S Lowe; Z Jia; J Norris; J Dong
Journal:  Gene Ther       Date:  2001-02       Impact factor: 5.250

Review 5.  Conditional gene targeting for cancer gene therapy.

Authors:  Y S Haviv; D T Curiel
Journal:  Adv Drug Deliv Rev       Date:  2001-12-17       Impact factor: 15.470

Review 6.  Transcriptional targeted gene therapy for hepatocellular carcinoma by adenovirus vector.

Authors:  F Kanai
Journal:  Mol Biotechnol       Date:  2001-07       Impact factor: 2.695

7.  Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells.

Authors:  F Andriani; B Nan; J Yu; X Li; N L Weigel; M J McPhaul; S Kasper; S Kagawa; B Fang; R J Matusik; L Denner; M Marcelli
Journal:  J Natl Cancer Inst       Date:  2001-09-05       Impact factor: 13.506

8.  Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.

Authors:  Christina Voelkel-Johnson; Deanne Lea King; James Scott Norris
Journal:  Cancer Gene Ther       Date:  2002-02       Impact factor: 5.987

9.  Technology evaluation: CV-787, Calydon Inc.

Authors:  C Doehn; D Jocham
Journal:  Curr Opin Mol Ther       Date:  2001-04

10.  A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.

Authors:  S Rubinchik; D Wang; H Yu; F Fan; M Luo; J S Norris; J Y Dong
Journal:  Mol Ther       Date:  2001-11       Impact factor: 11.454

View more
  2 in total

Review 1.  Advances in preclinical investigation of prostate cancer gene therapy.

Authors:  Marxa L Figueiredo; Chinghai Kao; Lily Wu
Journal:  Mol Ther       Date:  2007-04-24       Impact factor: 11.454

2.  Novel system uses probasin-based promoter, transcriptional silencers and amplification loop to induce high-level prostate expression.

Authors:  Jan Woraratanadharm; Semyon Rubinchik; Hong Yu; John Y Dong
Journal:  BMC Biotechnol       Date:  2007-02-12       Impact factor: 2.563

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.